Raphael Bodensohn1, Stefanie Corradini2, Ute Ganswindt2, Jan Hofmaier2, Oliver Schnell3, Claus Belka2,4,5, Maximilian Niyazi2,4,5. 1. Klinik und Poliklinik für Strahlentherapie und Radioonkologie, LMU Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. raphael.bodensohn@googlemail.com. 2. Klinik und Poliklinik für Strahlentherapie und Radioonkologie, LMU Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 3. Neurochirurgische Klinik und Poliklinik, LMU Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 4. German Cancer Consortium (DKTK), Munich, Germany. 5. German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Abstract
BACKGROUND: Neurocognition is a very important aspect of a brain tumor patient's quality of life following radiotherapy. The aim of the present study was to assess neurocognitive functions of patients diagnosed with high-grade gliomas undergoing radiotherapy by using the NeuroCogFx(®) test and to examine relevant dose/volume parameters as well as patient characteristics potentially influencing the neurological baseline status and subsequent outcome. METHODS: The cohort consisted of 44 astrocytoma World Health Organization grade III/IV patients. The NeuroCogFx(®) test was carried out on patients during (N = 44) and after (N = 21) irradiation. The test examines verbal/figural/short-term/working memory, psychomotorical speed, selective attention and verbal speed. The results were compared with regular patient and treatment data with an emphasis on the dose applied to the hippocampus. RESULTS: Overall there were only slight changes in the median test results when comparing the baseline to the follow-up tests. In the 'verbal memory test' lower percentile ranks were achieved in left-sided tumors compared to right-sided tumors (p = 0.034). Dexamethasone intake during radiotherapy was significantly correlated with the difference between the two test batteries. Concerning figural memory, a correlation was detected between decreased figural recognition and the radiation dose to the left hippocampus (p = 0.045). CONCLUSION: We conclude that tumor infiltration of the hippocampus has an impact on neurocognitive function. However, treatment with radiotherapy seems to have less influence on cognitive outcome than expected.
BACKGROUND: Neurocognition is a very important aspect of a brain tumorpatient's quality of life following radiotherapy. The aim of the present study was to assess neurocognitive functions of patients diagnosed with high-grade gliomas undergoing radiotherapy by using the NeuroCogFx(®) test and to examine relevant dose/volume parameters as well as patient characteristics potentially influencing the neurological baseline status and subsequent outcome. METHODS: The cohort consisted of 44 astrocytoma World Health Organization grade III/IV patients. The NeuroCogFx(®) test was carried out on patients during (N = 44) and after (N = 21) irradiation. The test examines verbal/figural/short-term/working memory, psychomotorical speed, selective attention and verbal speed. The results were compared with regular patient and treatment data with an emphasis on the dose applied to the hippocampus. RESULTS: Overall there were only slight changes in the median test results when comparing the baseline to the follow-up tests. In the 'verbal memory test' lower percentile ranks were achieved in left-sided tumors compared to right-sided tumors (p = 0.034). Dexamethasone intake during radiotherapy was significantly correlated with the difference between the two test batteries. Concerning figural memory, a correlation was detected between decreased figural recognition and the radiation dose to the left hippocampus (p = 0.045). CONCLUSION: We conclude that tumor infiltration of the hippocampus has an impact on neurocognitive function. However, treatment with radiotherapy seems to have less influence on cognitive outcome than expected.
Authors: Percy Lee; Wietse Eppinga; Frank Lagerwaard; Timothy Cloughesy; Benjamin Slotman; Phioanh L Nghiemphu; Pin-Chieh Wang; Patrick Kupelian; Nzhde Agazaryan; John Demarco; Michael T Selch; Michael Steinberg; Jung Julie Kang Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-22 Impact factor: 7.038
Authors: Patrick Evers; Percy P Lee; John DeMarco; Nzhde Agazaryan; James W Sayre; Michael Selch; Frank Pajonk Journal: BMC Cancer Date: 2010-07-21 Impact factor: 4.430
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Gisele Pereira Dias; Ronan Hollywood; Mário Cesar do Nascimento Bevilaqua; Anna Claudia Domingos da Silveira da Luz; Robert Hindges; Antonio Egidio Nardi; Sandrine Thuret Journal: Neuro Oncol Date: 2014-01-26 Impact factor: 12.300
Authors: Svetlana Zonis; Robert N Pechnick; Vladimir A Ljubimov; Michael Mahgerefteh; Kolja Wawrowsky; Kathrin S Michelsen; Vera Chesnokova Journal: J Neuroinflammation Date: 2015-04-03 Impact factor: 8.322
Authors: Michal Bienkowski; Anna S Berghoff; Christine Marosi; Adelheid Wöhrer; Harald Heinzl; Johannes A Hainfellner; Matthias Preusser Journal: Clin Neuropathol Date: 2015 Sep-Oct Impact factor: 1.368
Authors: Ivan Caramanna; Julie M de Kort; Alba A Brandes; Walter Taal; Michael Platten; Ahmed Idbaih; Jean Sebastien Frenel; Wolfgang Wick; Chandrakanth Jayachandran Preetha; Martin Bendszus; Philipp Vollmuth; Jaap C Reijneveld; Martin Klein Journal: Neurooncol Pract Date: 2022-03-13